EM, O., C, M., P, R., J, M., MJ, C., J, M., . . . MV, M. (2021). Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: Safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group.
Citación estilo ChicagoEM, Ocio, et al. Filanesib in Combination With Pomalidomide and Dexamethasone in Refractory MM Patients: Safety and Efficacy, and Association With Alpha 1-acid Glycoprotein (AAG) Levels. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group. 2021.
Cita MLAEM, Ocio, et al. Filanesib in Combination With Pomalidomide and Dexamethasone in Refractory MM Patients: Safety and Efficacy, and Association With Alpha 1-acid Glycoprotein (AAG) Levels. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group. 2021.